Novo Nordisk Kidney Disease Drug Trial Stopped Early After Positive Interim Results

Novo Nordisk study of Ozempic for chronic kidney disease halted early due to positive interim results

Independent review board recommended stopping trial almost a year ahead of schedule

Demand already high for Ozempic and sister drug Wegovy as weight loss treatments

Novo Nordisk ADRs jumped over 6% on news, shares of dialysis and insulin pump makers dropped

Study results expected in first half of 2023, designed to see if Ozempic could delay kidney disease progression